Navigation Links
Growth factor predicts poor outcome in breast cancer
Date:8/29/2008

The response to insulin-like growth factor 1 (IGF-I) in breast cancer cells predicts an aggressive tumor that is less likely to respond to treatment, said researchers at Baylor College of Medicine in a report that appears in the current issue of the Journal of Clinical Oncology. The finding gives impetus to the movement to tailor cancer treatments to attributes of the various tumors.

"These findings come at a critical time," said Dr. Adrian Lee, associate professor in the Lester and Sue Smith Breast Center at BCM. "Our goal is to identify biomarkers that will help predict which patients will respond to therapy against insulin-like growth factor. Several inhibitors of the IGF pathway are in patient studies right now. There's a large movement to understand which patients will respond to these drugs. This is a step toward that goal"

In this study, Lee and his colleagues stimulated breast cancer cells with IGF-I in the laboratory and defined how more than 800 genes in the cells responded to the growth factor. They then examined samples of patient breast tumors with this "gene signature" and correlated the gene signatures with the fate of the patients.

"We have technology now to allow us to globally assess what IGF is doing in breast cancer at the whole gene expression level," said Lee. "This is one of the first studies to do that. We know that IGF is bad in cancer, but now we can globally understand it in a more comprehensive manner. It could lead to finding biomarkers for patients response" to breast cancer treatments.

"We found that IGF-I is a major regulator of cell growth and cell survival," said Lee. "It also regulates DNA repair."

This has major implications for anti-cancer treatments that seek to cause DNA damage and tumor cell death.

"If you have something regulating DNA repair, you want that turned off," said Lee.

They found that tumors in which IGF (insulin-like growth factor) affe
'/>"/>

Contact: Kimberlee K. Norton
kknorton@bcm.edu
713-798-4710
Baylor College of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Heavy metal link to mutations, low growth and fertility among crustaceans in Sydney Harbor tributary
2. Hydrogels provide scaffolding for growth of bone cells
3. Zebra Technologies Enters Into Revolving Credit Agreement to Support Company Growth
4. Old growth giants limited by water-pulling ability
5. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
6. [video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.nets 3-Minute Press Show
7. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
8. Embryo biopsy does not affect early growth and risk of congenital malformations in PGD/PGS babies
9. Growth hormones link to starvation may be clue to increasing life span, researchers find
10. Blue light used to harden tooth fillings stunts tumor growth
11. Scientists find potential protein biomarkers for growth hormone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/8/2015)... May 8, 2015 Synaptics Inc. (NASDAQ: SYNA ... that members of the executive management team will present at ... Technology, Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company ... 2:45pm ET Location: The New York Palace Hotel, ...
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3
... Covalys Biosciences AG today announced a collaboration to ... generate SNAP-tag fusion proteins based on Gene Bridges' ... does not require restriction enzymes and allows the ... (bacterial artificial chromosomes) with single-nucleotide precision. SNAP-tag is ...
... Like humans, other animals are faced with everyday obstacles ... and motor skills to deal with them. Navigating these ... other vertebrates, but in new work, researchers have employed ... structure of goal-oriented motor programs in the fruit fly ...
... help stem the global HIV epidemic is to give ... drug tenofovir) before they have high risk sex in ... an approach called "pre-exposure prophylaxis" (PREP). But activist groups, ... least two important clinical trials of tenofovir as PREP ...
Cached Biology News:Gene Bridges And Covalys To Develop Restriction-Enzyme-Free SNAP-tag Gene Fusion Kits 2Gap-climbing fruit flies reveal components of goal-driven behaviors 2Why were the HIV prevention trials in commercial sex workers abandoned? 2
(Date:5/21/2015)... -- Prima Biomed Ltd. (NASDAQ: PBMD ) a globally ... leader in the development of immunotherapeutic products for the ... data from the Phase II CAN-003 ovarian cancer clinical ... meaningful improvement in Overall Survival ("OS") over standard of ... the group of second remission patients (n=20), the median ...
(Date:5/21/2015)... , May 21, 2015  The EveryLife ... Hatch (R-UT) and Amy Klobuchar ... Now Accelerating Cures & Treatments, or OPEN ACT. ... disease patient advocacy organizations, this bipartisan legislation promises ... affordable medicines to rare disease patients by incentivizing ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 W. ... its manufacturing facility in Worms, Germany has received ... independent subsidiary of the International Pharmaceutical Excipient Council ... facilities that produce its SYLOID® FP brand of ... GMP certification, following the Curtis Bay, Maryland (USA) ...
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
Breaking Biology Technology:Correction Continues after Big Move - BrokerBank Securities, Inc. 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
... Toronto Stock Exchange Symbol: LRILAVAL, QC, Feb. 9 /PRNewswire-FirstCall/ ... "Company") (TSX: LRI), a Canadian-based global non-clinical contract research ... Spalding as Chairman of its Board of Directors in ... wish to step down of the Board to focus ...
... and PARIS, February 9 Debiopharm,Group (Debiopharm), ... serious medical conditions and particularly oncology, and,Pharmaleads ... early development,company, today announced the signature of ... and commercialisation of a small molecule,called Debio ...
... 3SBio Inc.,(Nasdaq: SSRX ), a leading ... biopharmaceutical products primarily,in China, today announced that it ... effective February 1, 2009. Since joining 3SBio in ... financial advisor for the company, providing advice,on the ...
Cached Biology Technology:LAB Research announces changes to its Board of Directors 2Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions 2Debiopharm and Pharmaleads Sign License Agreement for Debio 0827 or PL37 in Treatment of Chronic Pain Conditions 33SBio Inc. Appoints Mr. Bo Tan as Chief Financial Officer 2
96 Well Plate EB, RE bottom; high binding irradiated surface to provide increased binding affinity for hydrophilic proteins and complexes. Guaranteed coefficient of variation (CVs)....
The Holten mini vertical flow workbench provides a particle-free environment for sample protection against airborne contaminants....
...
Medium bottle for hybridization 250 x 35mm...
Biology Products: